Erowid References Database
“Changing deathıs perspective”.
World Medicine. 1973;9(2):15-19.
The use of lysergic acid diethylamide (LSD) with dying patients is reported. Patients in the treatment program are selected as follows: having a terminal illness; be suffering emotional discomfort, physical pain, anxiety, tension of fear of death; the patient and the family must give informed consent; and the patient must have a survival expectancy of at least three months. The treatment falls into three phases -- preparation, the LSD. session, and subsequent drug free interviews. Results of the session reveal that patients are less anxious, depressed, socially withdrawn and do not suffer from insomnia. Value systems also change. The future of the treatment is
[ Cite HTML